In a significant move, President Trump has signed an executive order aimed at fast-tracking research and access to psychedelic drugs, particularly focusing on their potential to treat mental health disorders such as PTSD among veterans. The order, which has already led to a surge in shares of psychedelic drug developers, directs the FDA to accelerate the review process for psychedelics like ibogaine, LSD, and psilocybin. This initiative has sparked discussions and opinions on the promise of psychedelics in mental health treatment, amidst reactions from commentators and politicians. High-profile endorsements from figures like Joe Rogan and Conor McGregor have also highlighted the policy shift, raising hopes for new therapies while prompting questions about the broader implications for drug reclassification and cannabis reform.